Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · IEX Real-Time Price · USD
2.630
-0.060 (-2.23%)
At close: May 17, 2024, 4:00 PM
2.720
+0.090 (3.42%)
After-hours: May 17, 2024, 6:30 PM EDT
Gain Therapeutics Revenue
In the year 2023, Gain Therapeutics had annual revenue of $55.18K, a decrease of -60.62%.
Revenue (ttm)
$55.18K
Revenue Growth
-60.62%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
29
Market Cap
46.89M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 55.18K | -84.93K | -60.62% |
| Dec 31, 2022 | 140.11K | -24.89K | -15.08% |
| Dec 31, 2021 | 164.99K | 136.11K | 471.29% |
| Dec 31, 2020 | 28.88K | -12.42K | -30.07% |
| Dec 31, 2019 | 41.30K | 20.69K | 100.40% |
| Dec 31, 2018 | 20.61K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NeueHealth | 1.11B |
| Cutera | 196.64M |
| LENSAR | 44.50M |
| Aadi Bioscience | 23.84M |
| Aligos Therapeutics | 13.79M |
| Dyadic International | 2.26M |
| Clene | 620.00K |
GANX News
- 4 days ago - Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update - GlobeNewsWire
- 24 days ago - Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease - GlobeNewsWire
- 5 weeks ago - Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer - GlobeNewsWire
- 6 weeks ago - Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer - GlobeNewsWire
- 7 weeks ago - Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Gain Therapeutics to Present at Public Ventures Discovery Day - GlobeNewsWire
- 2 months ago - Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson's Disease - GlobeNewsWire
- 2 months ago - Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease - GlobeNewsWire